Royalty Pharma plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.3%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$3.5Bnext fiscal year
FY EPS (est.)
$5.33next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Portfolio Receipts Quarterly925MTarget: 3325000000 to 3450000000
Royalty Receipts Quarterly887MTarget: 4% to 8% growth
Capital Deployment Quarterly528MTarget: $1.5-2.0 billion in annual capital deployment on new royalty transactions
Watch Items
- Alyftrek Royalty DisputeTrigger: Any adverse interim arbitration ruling, settlement, or Vertex disclosure that would reduce expected cystic fibrosis franchise (Trikafta/Alyftrek) royalty receipts by more than 10% versus current modeled cash flowsAction: Monitor Royalty Pharma's quarterly filings, earnings calls and press releases for updates on the Vertex Pharmaceuticals arbitration; if the ruling is adverse, re-underwrite the cystic fibrosis (Trikafta/Alyftrek) royalty cash-flow assumptions and reduce the fair value estimate accordingly.
- Portfolio Concentration RiskAction: Track implementation of U.S. drug-pricing reforms (including IRA Medicare price negotiation rounds and CMS announcements); quantify the revenue exposure of the portfolio's top royalty-bearing products to negotiated prices and adjust royalty receipt forecasts and valuation if key products are selected or price impacts exceed modeled assumptions.
- Return on Invested Capital (ROIC)Trigger: Adjusted EBITDA leverage sustained above 4.0x net debt/EBITDA, or announced capital deployment exceeding available liquidity such that incremental debt issuance above investment-grade thresholds is required
Research as of 2 Sep 2026